These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1492230)

  • 41. The incidence of secondary leukemias.
    Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
    Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
    Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C
    J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
    Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT
    N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.
    Houck W; Abonour R; Vance G; Einhorn LH
    J Clin Oncol; 2004 Jun; 22(11):2155-8. PubMed ID: 15169802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secondary acute myelogenous leukemia following safe exposure to etoposide.
    Stine KC; Saylors RL; Sawyer JR; Becton DL
    J Clin Oncol; 1997 Apr; 15(4):1583-6. PubMed ID: 9193356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose etoposide (VP-16) in small-cell lung cancer.
    Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leukaemia during podophyllotoxin treatment in a patient with juvenile chronic arthritis.
    Kauppi M; Savolainen HA; Anttila VJ; Isomäki HA
    Scand J Rheumatol; 1996; 25(5):340. PubMed ID: 8921932
    [No Abstract]   [Full Text] [Related]  

  • 48. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L; Moffat J; Martins H; Glickman B
    Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?
    Boos J; Krümpelmann S; Schulze-Westhoff P; Euting T; Berthold F; Jürgens H
    J Clin Oncol; 1995 Dec; 13(12):2954-60. PubMed ID: 8523060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re: "Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X)" by Viana et al.
    Whitlock JA
    Med Pediatr Oncol; 1993; 21(5):379. PubMed ID: 8492755
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.
    Evans SR; Krown SE; Testa MA; Cooley TP; Von Roenn JH
    J Clin Oncol; 2002 Aug; 20(15):3236-41. PubMed ID: 12149296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxicity of the topoisomerase II inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Mar; 4(2):219-34. PubMed ID: 15794715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
    Ratain MJ; Schilsky RL; Choi KE; Guarnieri C; Grimmer D; Vogelzang NJ; Senekjian E; Liebner MA
    Clin Pharmacol Ther; 1989 Mar; 45(3):226-33. PubMed ID: 2920497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose etoposide for refractory malignancies: a phase I study.
    Postmus PE; Mulder NH; Sleijfer DT; Meinesz AF; Vriesendorp R; de Vries EG
    Cancer Treat Rep; 1984 Dec; 68(12):1471-4. PubMed ID: 6509453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer.
    Lopez JA; Mann J; Grapski RT; Nassif E; Vannicola P; Krikorian JG; Finkel H
    Cancer Treat Rep; 1985 Apr; 69(4):369-71. PubMed ID: 2986833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
    Yashiki C; Hirose T; Sugiyama T; Kusumoto S; Shirai T; Ohmori T; Adachi M; Nakamura A
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):245-9. PubMed ID: 20154478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
    Miller AA; Tolley EA; Niell HB
    Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary pre-leukaemia and etoposide.
    Lancet; 1991 Nov; 338(8777):1269-70. PubMed ID: 1682661
    [No Abstract]   [Full Text] [Related]  

  • 60. A tool for neutrophil guided dose adaptation in chemotherapy.
    Wallin JE; Friberg LE; Karlsson MO
    Comput Methods Programs Biomed; 2009 Mar; 93(3):283-91. PubMed ID: 19084287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.